Pathogenesis, Diagnosis, and Management of Cholangiocarcinoma

Welzel, 2006, Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the United States, J Natl Cancer Inst, 98, 873, 10.1093/jnci/djj234 Blechacz, 2011, Clinical diagnosis and staging of cholangiocarcinoma, Nat Rev Gastroenterol Hepatol, 8, 512, 10.1038/nrgastro.2011.131 Deoliveira, 2011, New staging system and a registry for perihilar cholangiocarcinoma, Hepatology, 53, 1363, 10.1002/hep.24227 DeOliveira, 2007, Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution, Ann Surg, 245, 755, 10.1097/01.sla.0000251366.62632.d3 Blechacz BG, Gores, GJ. Tumors of the bile ducts, gallbladder, and ampulla. In: Feldman, ed. Sleisenger and Fordtran's gastrointestinal and liver disease. Volume 1. 9th ed. Philadelphia: Saunders, 2010:1171–1176. Khan, 2012, Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update, Gut, 61, 1657, 10.1136/gutjnl-2011-301748 Everhart, 2009, Burden of digestive diseases in the United States part III: liver, biliary tract, and pancreas, Gastroenterology, 136, 1134, 10.1053/j.gastro.2009.02.038 Tyson, 2011, Risk factors for cholangiocarcinoma, Hepatology, 54, 173, 10.1002/hep.24351 Shaib, 2004, The epidemiology of cholangiocarcinoma, Semin Liver Dis, 24, 115, 10.1055/s-2004-828889 Sripa, 2008, Cholangiocarcinoma: lessons from Thailand, Curr Opin Gastroenterol, 24, 349, 10.1097/MOG.0b013e3282fbf9b3 Khan, 2002, Changing international trends in mortality rates for liver, biliary and pancreatic tumours, J Hepatol, 37, 806, 10.1016/S0168-8278(02)00297-0 Khan, 2008, Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma, HPB (Oxford), 10, 77, 10.1080/13651820801992641 McGlynn, 2006, A comparison of trends in the incidence of hepatocellular carcinoma and intrahepatic cholangiocarcinoma in the United States, Cancer Epidemiol Biomarkers Prev, 15, 1198, 10.1158/1055-9965.EPI-05-0811 Patel, 2001, Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States, Hepatology, 33, 1353, 10.1053/jhep.2001.25087 Patel, 2002, Worldwide trends in mortality from biliary tract malignancies, BMC Cancer, 2, 10, 10.1186/1471-2407-2-10 Khan, 2012, Rising trends in cholangiocarcinoma: is the ICD classification system misleading us?, J Hepatol, 56, 848, 10.1016/j.jhep.2011.11.015 Razumilava, 2013, Classification, diagnosis, and management of cholangiocarcinoma, Clin Gastroenterol Hepatol, 11, 13, 10.1016/j.cgh.2012.09.009 Shin, 2010, Descriptive epidemiology of cholangiocarcinoma and clonorchiasis in Korea, J Korean Med Sci, 25, 1011, 10.3346/jkms.2010.25.7.1011 Huang, 2005, Relation of hepatolithiasis to helminthic infestation, J Gastroenterol Hepatol, 20, 141, 10.1111/j.1440-1746.2004.03523.x Edil, 2008, Choledochal cyst disease in children and adults: a 30-year single-institution experience, J Am Coll Surg, 206, 1000, 10.1016/j.jamcollsurg.2007.12.045 Mabrut, 2010, Management of congenital bile duct cysts, Dig Surg, 27, 12, 10.1159/000268109 Kato, 1987, Increased risk of death in thorotrast-exposed patients during the late follow-up period, Jpn J Cancer Res, 78, 1187 Lee, 2008, Hepatitis B virus infection and intrahepatic cholangiocarcinoma in Korea: a case-control study, Am J Gastroenterol, 103, 1716, 10.1111/j.1572-0241.2008.01796.x Shaib, 2007, Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a hospital-based case-control study, Am J Gastroenterol, 102, 1016, 10.1111/j.1572-0241.2007.01104.x Sorensen, 1998, Risk of liver and other types of cancer in patients with cirrhosis: a nationwide cohort study in Denmark, Hepatology, 28, 921, 10.1002/hep.510280404 Palmer, 2012, Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma, J Hepatol, 57, 69, 10.1016/j.jhep.2012.02.022 Shaib, 2005, Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study, Gastroenterology, 128, 620, 10.1053/j.gastro.2004.12.048 Welzel, 2007, Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study, Clin Gastroenterol Hepatol, 5, 1221, 10.1016/j.cgh.2007.05.020 Welzel, 2007, Risk factors for intrahepatic cholangiocarcinoma in a low-risk population: a nationwide case-control study, Int J Cancer, 120, 638, 10.1002/ijc.22283 Nakanuma, 2010, Pathological classification of intrahepatic cholangiocarcinoma based on a new concept, World J Hepatol, 2, 419, 10.4254/wjh.v2.i12.419 Komuta, 2008, Clinicopathological study on cholangiolocellular carcinoma suggesting hepatic progenitor cell origin, Hepatology, 47, 1544, 10.1002/hep.22238 Tsuchiya, 2011, Hepatocellular carcinoma with progenitor cell features distinguishable by the hepatic stem/progenitor cell marker NCAM, Cancer Lett, 309, 95, 10.1016/j.canlet.2011.05.021 Cardinale, 2012, Multiple cells of origin in cholangiocarcinoma underlie biological, epidemiological and clinical heterogeneity, World J Gastrointest Oncol, 4, 94, 10.4251/wjgo.v4.i5.94 Komuta, 2012, Histological diversity in cholangiocellular carcinoma reflects the different cholangiocyte phenotypes, Hepatology, 55, 1876, 10.1002/hep.25595 Fan, 2012, Cholangiocarcinomas can originate from hepatocytes in mice, J Clin Invest, 122, 2911, 10.1172/JCI63212 Sekiya, 2012, Intrahepatic cholangiocarcinoma can arise from Notch-mediated conversion of hepatocytes, J Clin Invest, 122, 3914, 10.1172/JCI63065 Holczbauer, 2013, Modeling pathogenesis of primary liver cancer in lineage-specific mouse cell types, Gastroenterology, 145, 221, 10.1053/j.gastro.2013.03.013 Jaiswal, 2000, Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism, Cancer Res, 60, 184 Park, 1999, Inhibition of interleukin 6-mediated mitogen-activated protein kinase activation attenuates growth of a cholangiocarcinoma cell line, Hepatology, 30, 1128, 10.1002/hep.510300522 Kobayashi, 2005, Interleukin-6 contributes to Mcl-1 up-regulation and TRAIL resistance via an Akt-signaling pathway in cholangiocarcinoma cells, Gastroenterology, 128, 2054, 10.1053/j.gastro.2005.03.010 Taniai, 2004, Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells, Cancer Res, 64, 3517, 10.1158/0008-5472.CAN-03-2770 Isomoto, 2005, Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma cells, Hepatology, 42, 1329, 10.1002/hep.20966 Meng, 2006, Over-expression of interleukin-6 enhances cell survival and transformed cell growth in human malignant cholangiocytes, J Hepatol, 44, 1055, 10.1016/j.jhep.2005.10.030 Sia, 2013, Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies, Oncogene, 32, 4861, 10.1038/onc.2012.617 Sia, 2013, Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes, Gastroenterology, 144, 829, 10.1053/j.gastro.2013.01.001 Isomoto, 2007, Sustained IL-6/STAT-3 signaling in cholangiocarcinoma cells due to SOCS-3 epigenetic silencing, Gastroenterology, 132, 384, 10.1053/j.gastro.2006.10.037 Yoon, 2004, Enhanced epidermal growth factor receptor activation in human cholangiocarcinoma cells, J Hepatol, 41, 808, 10.1016/j.jhep.2004.07.016 Kiguchi, 2001, Constitutive expression of ErbB-2 in gallbladder epithelium results in development of adenocarcinoma, Cancer Res, 61, 6971 Matsumoto, 2006, Hepatocyte growth factor and the Met system as a mediator of tumor-stromal interactions, Int J Cancer, 119, 477, 10.1002/ijc.21808 Nishimura, 1999, Prostate stromal cell-derived hepatocyte growth factor induces invasion of prostate cancer cell line DU145 through tumor-stromal interaction, Prostate, 41, 145, 10.1002/(SICI)1097-0045(19991101)41:3<145::AID-PROS1>3.0.CO;2-R Nakamura, 1997, Induction of hepatocyte growth factor in fibroblasts by tumor-derived factors affects invasive growth of tumor cells: in vitro analysis of tumor-stromal interactions, Cancer Res, 57, 3305 Comoglio, 2008, Drug development of MET inhibitors: targeting oncogene addiction and expedience, Nat Rev Drug Discov, 7, 504, 10.1038/nrd2530 Lai, 2000, Unique epithelial cell production of hepatocyte growth factor/scatter factor by putative precancerous intestinal metaplasias and associated “intestinal-type” biliary cancer chemically induced in rat liver, Hepatology, 31, 1257, 10.1053/jhep.2000.8108 Miyamoto, 2011, Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma, Br J Cancer, 105, 131, 10.1038/bjc.2011.199 Radaeva, 1999, Overexpression of C-NEU and C-MET during rat liver cholangiocarcinogenesis: a link between biliary intestinal metaplasia and mucin-producing cholangiocarcinoma, Hepatology, 29, 1453, 10.1002/hep.510290524 Yoon, 2002, Bile acids induce cyclooxygenase-2 expression via the epidermal growth factor receptor in a human cholangiocarcinoma cell line, Gastroenterology, 122, 985, 10.1053/gast.2002.32410 Yoon, 2004, Oxysterols induce cyclooxygenase-2 expression in cholangiocytes: implications for biliary tract carcinogenesis, Hepatology, 39, 732, 10.1002/hep.20125 Kuver, 2012, Mechanisms of oxysterol-induced disease: insights from the biliary system, Clin Lipidol, 7, 537, 10.2217/clp.12.53 Nachtergaele, 2012, Oxysterols are allosteric activators of the oncoprotein Smoothened, Nat Chem Biol, 8, 211, 10.1038/nchembio.765 Fingas, 2011, Myofibroblast-derived PDGF-BB promotes Hedgehog survival signaling in cholangiocarcinoma cells, Hepatology, 54, 2076, 10.1002/hep.24588 Andersen, 2012, Genetic profiling of intrahepatic cholangiocarcinoma, Curr Opin Gastroenterol, 28, 266, 10.1097/MOG.0b013e3283523c7e McKay, 2011, Array comparative genomic hybridization identifies novel potential therapeutic targets in cholangiocarcinoma, HPB (Oxford), 13, 309, 10.1111/j.1477-2574.2010.00286.x Koo, 2001, Genetic alterations in hepatocellular carcinoma and intrahepatic cholangiocarcinoma, Cancer Genet Cytogenet, 130, 22, 10.1016/S0165-4608(01)00460-5 Uhm, 2005, Chromosomal imbalances in Korean intrahepatic cholangiocarcinoma by comparative genomic hybridization, Cancer Genet Cytogenet, 157, 37, 10.1016/j.cancergencyto.2004.05.007 Lee, 2004, Genetic alterations in intrahepatic cholangiocarcinoma as revealed by degenerate oligonucleotide primed PCR-comparative genomic hybridization, J Korean Med Sci, 19, 682, 10.3346/jkms.2004.19.5.682 Wong, 2002, Frequent loss of chromosome 3p and hypermethylation of RASSF1A in cholangiocarcinoma, J Hepatol, 37, 633, 10.1016/S0168-8278(02)00269-6 Homayounfar, 2009, Pattern of chromosomal aberrations in primary liver cancers identified by comparative genomic hybridization, Hum Pathol, 40, 834, 10.1016/j.humpath.2008.11.005 Ong, 2012, Exome sequencing of liver fluke-associated cholangiocarcinoma, Nat Genet, 44, 690, 10.1038/ng.2273 Xu, 2011, KRAS and PIK3CA but not BRAF genes are frequently mutated in Chinese cholangiocarcinoma patients, Biomed Pharmacother, 65, 22, 10.1016/j.biopha.2010.06.009 Ohashi, 1995, Ki-ras mutations and p53 protein expressions in intrahepatic cholangiocarcinomas: relation to gross tumor morphology, Gastroenterology, 109, 1612, 10.1016/0016-5085(95)90650-9 Andersen, 2012, Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors, Gastroenterology, 142, 1021, 10.1053/j.gastro.2011.12.005 Tada, 1992, High incidence of ras gene mutation in intrahepatic cholangiocarcinoma, Cancer, 69, 1115, 10.1002/cncr.2820690509 Khan, 2005, p53 Mutations in human cholangiocarcinoma: a review, Liver Int, 25, 704, 10.1111/j.1478-3231.2005.01106.x Kipp, 2012, Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma, Hum Pathol, 43, 1552, 10.1016/j.humpath.2011.12.007 Borger, 2012, Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping, Oncologist, 17, 72, 10.1634/theoncologist.2011-0386 Wang, 2013, Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas, Oncogene, 32, 3091, 10.1038/onc.2012.315 Reitman, 2010, IDH1 and IDH2: not your typical oncogenes, Cancer Cell, 17, 215, 10.1016/j.ccr.2010.02.024 Rohle, 2013, An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells, Science, 340, 626, 10.1126/science.1236062 Wang, 2013, Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation, Science, 340, 622, 10.1126/science.1234769 Oishi, 2012, Transcriptomic profiling reveals hepatic stem-like gene signatures and interplay of miR-200c and epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma, Hepatology, 56, 1792, 10.1002/hep.25890 Chen, 2009, The role of microRNA expression pattern in human intrahepatic cholangiocarcinoma, J Hepatol, 50, 358, 10.1016/j.jhep.2008.09.015 Wu, 2013, Identification of targetable FGFR gene fusions in diverse cancers, Cancer Discov, 3, 636, 10.1158/2159-8290.CD-13-0050 Yamanaka, 2012, MicroRNA-21 inhibits Serpini1, a gene with novel tumour suppressive effects in gastric cancer, Dig Liver Dis, 44, 589, 10.1016/j.dld.2012.02.016 Meng, 2006, Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines, Gastroenterology, 130, 2113, 10.1053/j.gastro.2006.02.057 Hofmann, 2010, Jagged1 in the portal vein mesenchyme regulates intrahepatic bile duct development: insights into Alagille syndrome, Development, 137, 4061, 10.1242/dev.052118 Zender, 2013, A critical role for notch signaling in the formation of cholangiocellular carcinomas, Cancer Cell, 23, 784, 10.1016/j.ccr.2013.04.019 Jinawath, 2007, Dual blockade of the Hedgehog and ERK1/2 pathways coordinately decreases proliferation and survival of cholangiocarcinoma cells, J Cancer Res Clin Oncol, 133, 271, 10.1007/s00432-006-0166-9 El Khatib, 2013, Inhibition of hedgehog signaling attenuates carcinogenesis in vitro and increases necrosis of cholangiocellular carcinoma, Hepatology, 57, 1035, 10.1002/hep.26147 Sirica, 2008, Pathobiology of biliary epithelia and cholangiocarcinoma: proceedings of the Henry M. and Lillian Stratton Basic Research Single-Topic Conference, Hepatology, 48, 2040, 10.1002/hep.22623 Tanaka, 2003, Human WISP1v, a member of the CCN family, is associated with invasive cholangiocarcinoma, Hepatology, 37, 1122, 10.1053/jhep.2003.50187 Junttila, 2013, Influence of tumour micro-environment heterogeneity on therapeutic response, Nature, 501, 346, 10.1038/nature12626 Sirica, 2012, The role of cancer-associated myofibroblasts in intrahepatic cholangiocarcinoma, Nat Rev Gastroenterol Hepatol, 9, 44, 10.1038/nrgastro.2011.222 Kalluri, 2006, Fibroblasts in cancer, Nat Rev Cancer, 6, 392, 10.1038/nrc1877 Dranoff, 2010, Portal fibroblasts: underappreciated mediators of biliary fibrosis, Hepatology, 51, 1438, 10.1002/hep.23405 Okabe, 2009, Hepatic stellate cells may relate to progression of intrahepatic cholangiocarcinoma, Ann Surg Oncol, 16, 2555, 10.1245/s10434-009-0568-4 Quante, 2011, Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth, Cancer Cell, 19, 257, 10.1016/j.ccr.2011.01.020 Li, 2010, Epithelial-mesenchymal transition induced by hepatitis C virus core protein in cholangiocarcinoma, Ann Surg Oncol, 17, 1937, 10.1245/s10434-010-0925-3 Sato, 2010, Epithelial-mesenchymal transition induced by transforming growth factor-{beta}1/Snail activation aggravates invasive growth of cholangiocarcinoma, Am J Pathol, 177, 141, 10.2353/ajpath.2010.090747 Korita, 2010, Aberrant expression of vimentin correlates with dedifferentiation and poor prognosis in patients with intrahepatic cholangiocarcinoma, Anticancer Res, 30, 2279 Cadamuro, 2013, Platelet-derived growth factor-D and Rho GTPases regulate recruitment of cancer-associated fibroblasts in cholangiocarcinoma, Hepatology, 58, 1042, 10.1002/hep.26384 Fingas, 2012, Targeting PDGFR-beta in cholangiocarcinoma, Liver Int, 32, 400 Utispan, 2010, Gene expression profiling of cholangiocarcinoma-derived fibroblast reveals alterations related to tumor progression and indicates periostin as a poor prognostic marker, Mol Cancer, 9, 13, 10.1186/1476-4598-9-13 Baril, 2007, Periostin promotes invasiveness and resistance of pancreatic cancer cells to hypoxia-induced cell death: role of the beta4 integrin and the PI3k pathway, Oncogene, 26, 2082, 10.1038/sj.onc.1210009 Menakongka, 2010, Involvement of PI3K and ERK1/2 pathways in hepatocyte growth factor-induced cholangiocarcinoma cell invasion, World J Gastroenterol, 16, 713, 10.3748/wjg.v16.i6.713 Ohira, 2006, Possible regulation of migration of intrahepatic cholangiocarcinoma cells by interaction of CXCR4 expressed in carcinoma cells with tumor necrosis factor-alpha and stromal-derived factor-1 released in stroma, Am J Pathol, 168, 1155, 10.2353/ajpath.2006.050204 Leelawat, 2007, Roles of the MEK1/2 and AKT pathways in CXCL12/CXCR4 induced cholangiocarcinoma cell invasion, World J Gastroenterol, 13, 1561, 10.3748/wjg.v13.i10.1561 Terada, 1996, Expression of immunoreactive matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in human normal livers and primary liver tumors, Hepatology, 23, 1341, 10.1002/hep.510230608 Prakobwong, 2010, Involvement of MMP-9 in peribiliary fibrosis and cholangiocarcinogenesis via Rac1-dependent DNA damage in a hamster model, Int J Cancer, 127, 2576, 10.1002/ijc.25266 Cohen, 2008, Fibroblast activation protein and its relationship to clinical outcome in pancreatic adenocarcinoma, Pancreas, 37, 154, 10.1097/MPA.0b013e31816618ce Mertens, 2013, Therapeutic effects of deleting cancer-associated fibroblasts in cholangiocarcinoma, Cancer Res, 73, 897, 10.1158/0008-5472.CAN-12-2130 Ko, 2013, Animal models of cholangiocarcinoma, Curr Opin Gastroenterol, 29, 312, 10.1097/MOG.0b013e32835d6a3e Fava, 2005, gamma-Aminobutyric acid inhibits cholangiocarcinoma growth by cyclic AMP-dependent regulation of the protein kinase A/extracellular signal-regulated kinase 1/2 pathway, Cancer Res, 65, 11437, 10.1158/0008-5472.CAN-05-1470 Pawar, 2009, Molecular mechanisms of tamoxifen therapy for cholangiocarcinoma: role of calmodulin, Clin Cancer Res, 15, 1288, 10.1158/1078-0432.CCR-08-1150 Tang, 2007, Effects of targeting magnetic drug nanoparticles on human cholangiocarcinoma xenografts in nude mice, Hepatobiliary Pancreat Dis Int, 6, 303 Zhang, 2012, MicroRNA-26a promotes cholangiocarcinoma growth by activating beta-catenin, Gastroenterology, 143, 246, 10.1053/j.gastro.2012.03.045 Olaru, 2011, MicroRNA down-regulated in human cholangiocarcinoma control cell cycle through multiple targets involved in the G1/S checkpoint, Hepatology, 54, 2089, 10.1002/hep.24591 Zhang, 2011, RNA interference targeting slug increases cholangiocarcinoma cell sensitivity to cisplatin via upregulating PUMA, Int J Mol Sci, 12, 385, 10.3390/ijms12010385 Obchoei, 2011, Cyclophilin A enhances cell proliferation and tumor growth of liver fluke-associated cholangiocarcinoma, Mol Cancer, 10, 102, 10.1186/1476-4598-10-102 Hou, 2011, Inhibition of active autophagy induces apoptosis and increases chemosensitivity in cholangiocarcinoma, Lab Invest, 91, 1146, 10.1038/labinvest.2011.97 Xu, 2006, Induction of intrahepatic cholangiocellular carcinoma by liver-specific disruption of Smad4 and Pten in mice, J Clin Invest, 116, 1843, 10.1172/JCI27282 Farazi, 2006, Chronic bile duct injury associated with fibrotic matrix microenvironment provokes cholangiocarcinoma in p53-deficient mice, Cancer Res, 66, 6622, 10.1158/0008-5472.CAN-05-4609 Song, 2010, Mammalian Mst1 and Mst2 kinases play essential roles in organ size control and tumor suppression, Proc Natl Acad Sci U S A, 107, 1431, 10.1073/pnas.0911409107 Lee, 2010, The Hippo-Salvador pathway restrains hepatic oval cell proliferation, liver size, and liver tumorigenesis, Proc Natl Acad Sci U S A, 107, 8248, 10.1073/pnas.0912203107 O'Dell, 2012, Kras(G12D) and p53 mutation cause primary intrahepatic cholangiocarcinoma, Cancer Res, 72, 1557, 10.1158/0008-5472.CAN-11-3596 Sirica, 2008, A novel “patient-like” model of cholangiocarcinoma progression based on bile duct inoculation of tumorigenic rat cholangiocyte cell lines, Hepatology, 47, 1178, 10.1002/hep.22088 Campbell, 2012, Novel organotypic culture model of cholangiocarcinoma progression, Hepatol Res, 42, 1119, 10.1111/j.1872-034X.2012.01026.x Fava, 2008, Leptin enhances cholangiocarcinoma cell growth, Cancer Res, 68, 6752, 10.1158/0008-5472.CAN-07-6682 Yang, 2011, A mouse model of cholestasis-associated cholangiocarcinoma and transcription factors involved in progression, Gastroenterology, 141, 378, 10.1053/j.gastro.2011.03.044 Plengsuriyakarn, 2012, Ultrasonography as a tool for monitoring the development and progression of cholangiocarcinoma in Opisthorchis viverrini/dimethylnitrosamine-induced hamsters, Asian Pac J Cancer Prev, 13, 87, 10.7314/APJCP.2012.13.1.087 Yamasaki, 2003, Intrahepatic cholangiocarcinoma: macroscopic type and stage classification, J Hepatobiliary Pancreat Surg, 10, 288, 10.1007/s00534-002-0732-8 Rimola, 2009, Cholangiocarcinoma in cirrhosis: absence of contrast washout in delayed phases by magnetic resonance imaging avoids misdiagnosis of hepatocellular carcinoma, Hepatology, 50, 791, 10.1002/hep.23071 Vilgrain, 2008, Staging cholangiocarcinoma by imaging studies, HPB (Oxford), 10, 106, 10.1080/13651820801992617 Blechacz, 2008, Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment, Hepatology, 48, 308, 10.1002/hep.22310 Patel, 2000, The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis, Am J Gastroenterol, 95, 204, 10.1111/j.1572-0241.2000.01685.x Sapisochin, 2011, Mixed hepatocellular cholangiocarcinoma and intrahepatic cholangiocarcinoma in patients undergoing transplantation for hepatocellular carcinoma, Liver Transpl, 17, 934, 10.1002/lt.22307 Endo, 2008, Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection, Ann Surg, 248, 84, 10.1097/SLA.0b013e318176c4d3 Choi, 2009, The prognosis and survival outcome of intrahepatic cholangiocarcinoma following surgical resection: association of lymph node metastasis and lymph node dissection with survival, Ann Surg Oncol, 16, 3048, 10.1245/s10434-009-0631-1 Li, 2011, Prognostic value of cirrhosis for intrahepatic cholangiocarcinoma after surgical treatment, J Gastrointest Surg, 15, 608, 10.1007/s11605-011-1419-8 Fabris, 2011, Nuclear expression of S100A4 calcium-binding protein increases cholangiocarcinoma invasiveness and metastasization, Hepatology, 54, 890, 10.1002/hep.24466 Kuhlmann, 2013, Locoregional therapy for cholangiocarcinoma, Curr Opin Gastroenterol, 29, 324, 10.1097/MOG.0b013e32835d9dea Valle, 2010, Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer, N Engl J Med, 362, 1273, 10.1056/NEJMoa0908721 Yamashita, 1992, Hilar cholangiocarcinoma. An evaluation of subtypes with CT and angiography, Acta Radiol, 33, 351, 10.1177/028418519203300413 Heimbach, 2011, Trans-peritoneal fine needle aspiration biopsy of hilar cholangiocarcinoma is associated with disease dissemination, HPB (Oxford), 13, 356, 10.1111/j.1477-2574.2011.00298.x Moreno Luna, 2006, Advanced cytologic techniques for the detection of malignant pancreatobiliary strictures, Gastroenterology, 131, 1064, 10.1053/j.gastro.2006.08.021 Barr Fritcher, 2011, Primary sclerosing cholangitis patients with serial polysomy fluorescence in situ hybridization results are at increased risk of cholangiocarcinoma, Am J Gastroenterol, 106, 2023, 10.1038/ajg.2011.272 Barr Fritcher, 2013, Primary sclerosing cholangitis with equivocal cytology: fluorescence in situ hybridization and serum CA 19–9 predict risk of malignancy, Cancer Cytopathol, 10.1002/cncy.21331 Nagorney, 2006, Hepatic resection in the treatment of hilar cholangiocarcinoma, Adv Surg, 40, 159, 10.1016/j.yasu.2006.05.009 Darwish Murad, 2012, Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers, Gastroenterology, 143, 88, 10.1053/j.gastro.2012.04.008 Hong, 2011, Comparative analysis of resection and liver transplantation for intrahepatic and hilar cholangiocarcinoma: a 24-year experience in a single center, Arch Surg, 146, 683, 10.1001/archsurg.2011.116 Geynisman, 2012, Toward personalized treatment of advanced biliary tract cancers, Discov Med, 14, 41